The Finnish pharmaceutical sector saw fluctuations in output from 2013 to 2023, reflected by a series of rises and dips. Particularly noteworthy periods include 2016, when a significant growth of 19.35% was noted, and 2022's 17.34% rise, signaling strong sectoral rebounds. However, declines were also notable: a 3.2% drop in 2020 and smaller dips in 2018 and 2019. By 2023, this sector reached 2.57 Billion Euros, translating to a modest 2.26% year-on-year growth.

From 2019 onward, the sector saw modest growth with an overall 5-year CAGR of 2.06% forecasted for 2024-2028, indicating a steady but moderate increase. By 2028, the forecast indicates a 10.76% growth from 2023 levels.

Future trends to watch for:

Advancements in biotechnology and personalized medicine enriching product pipelines.
Impact of increased R&D investments on output and competitiveness.
Regulatory changes and their effect on market dynamics.
Global market fluctuations and their influence on Finnish exports.